Filing Flows

Filing Flows › 8-K events › Iovance Biotherapeutics

Iovance Biotherapeutics: other events

Form 8-K filed Oct 29, 2026 · items 8.01

FDA decisionsIovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

What the filing says

202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Iovance Biotherapeutics at a glance

Latest quarterQ3 2026
Revenue$121.5M
Revenue Y/Y+80%
Operating margin-19.7%
IndustryBiological Products, (No Diagnostic Substances)

Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%. The chart follows the revenue to costs, profit and cash.

Iovance Biotherapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.